NCT05320094 is a Phase 1 clinical trial of Mavacamten in Healthy Participants, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT05320094?

NCT05320094 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT05320094?

Interventions in NCT05320094: Mavacamten, Activated Charcoal with Sorbitol.

What condition does NCT05320094 study?

NCT05320094 studies Healthy Participants.

Is NCT05320094 still recruiting?

NCT05320094 is currently completed. Last updated 8 November 2022.

Last reviewed 2022-11-08 · How we verify

NCT05320094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Completed Phase 1 Last updated 8 November 2022

What this trial tests

Phase 1 trial testing Mavacamten in Healthy Participants in 45 participants. Completed in 11 September 2022.

Timeline

15 April 2022

Primary endpoint
11 September 2022

11 September 2022

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	15 April 2022
Primary completion	11 September 2022
Estimated completion	11 September 2022
Sites	1 location across United States

Drugs / interventions tested

Mavacamten (MAVACAMTEN) — full drug profile →
Activated Charcoal with Sorbitol — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 60, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose drug levels of mavacamten in healthy participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants.
Merali S, Chiang M, Sychterz C, Chao L, et al · · 2024 · PMID 38926266 · DOI 10.1007/s40256-024-00659-z

Verify or expand the search:

Other trials of Mavacamten

Trials testing the same drug.

NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
NCT07004972 — A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) · Phase 4 · recruiting
NCT07383025 — Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan · recruiting
NCT06856265 — Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardi · NA · not yet recruiting
NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05320094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 8 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05320094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing